Legal status · United States
Is Nimacimab legal in the United States?
No. Nimacimab is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
Nimacimab in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| FDA approval status | Investigational; Phase 2 |
| Evidence level | Preliminary (research strength: Moderate) |
| Reviewed | Sep 2026 |
Classification and note come from the Nimacimab profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
Nimacimab is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Nimacimab is
An antibody that blocks the cannabinoid CB1 receptor outside the brain; alone it did little, but with semaglutide it reached 22.3% weight loss at 52 weeks and halved regain during a drug holiday.
Nimacimab (Skye Bioscience) is a negative allosteric modulator antibody that cannot cross into the brain, an attempt to keep the metabolic benefit of CB1 blockade without the psychiatric effects that sank rimonabant. 3% at 52 weeks in the extension.
Mechanism: Negative allosteric modulation of CB1 receptors in fat, liver and gut, reducing lipogenesis and improving insulin sensitivity without central nervous system exposure.
Regulatory history: Investigational; Phase 2
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Nimacimab at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Nimacimab in other countries
Frequently asked questions
Is Nimacimab legal in the United States?
No. Nimacimab is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Preliminary.
Can I buy Nimacimab in the United States?
No approved product exists to buy. In the United States Nimacimab is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is Nimacimab FDA approved?
No. FDA status: Investigational; Phase 2. Current US classification: "Investigational, not approved". Evidence level: Preliminary.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Nimacimab live on its compound profile.
Nimacimab profileThis page is general information about the regulatory status of Nimacimab in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.